ABSI
NASDAQAbsci Corporation
Price$6.64-0.16 (-2.29%)
01:30 PM03:00 PM
News · 26 weeks56+25%
2025-12-142026-06-07
Mix3290d
- Insider12(38%)
- SEC Filings8(25%)
- Other7(22%)
- Earnings3(9%)
- Analyst2(6%)
Latest news
25 items- INSIDERDirector Szela Mary T was granted 10,100 shares (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Pangalos Menelas N was granted 10,100 shares, increasing direct ownership by 4% to 242,408 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Van Houten Frans was granted 10,100 shares, increasing direct ownership by 16% to 73,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Rabinovitsj Daniel A was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Sirosh Joseph was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- SECAbsci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Absci Corp (0001672688) (Filer)
- ANALYSTLeerink Partners initiated coverage on Absci Corporation with a new price targetLeerink Partners initiated coverage of Absci Corporation with a rating of Outperform and set a new price target of $12.00
- INSIDERCFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,319 shares, decreasing direct ownership by 2% to 491,464 units (SEC Form 4) to satisfy withholding tax4 - Absci Corp (0001672688) (Issuer)
- ANALYSTBTIG Research initiated coverage on Absci Corporation with a new price targetBTIG Research initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00
- PRAbsci to Participate in Upcoming Investor ConferencesVANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference (New York, NY)Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time Interested parties may access live and archived webcasts of the presentations on the company's
- INSIDERDirector Pangalos Menelas N bought $200,748 worth of shares (37,453 units at $5.36), increasing direct ownership by 19% to 232,308 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- SECSEC Form 10-Q filed by Absci Corporation10-Q - Absci Corp (0001672688) (Filer)
- SECAbsci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
- PRAbsci Reports Business Updates and First Quarter 2026 Financial and Operating ResultsSuccessfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the
- PRAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the "Inducement Plan"), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nas
- PRAbsci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The
- SECSEC Form DEF 14A filed by Absci CorporationDEF 14A - Absci Corp (0001672688) (Filer)
- SECSEC Form DEFA14A filed by Absci CorporationDEFA14A - Absci Corp (0001672688) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Absci CorporationSCHEDULE 13D/A - Absci Corp (0001672688) (Subject)
- PRAbsci to Participate in the 25th Annual Needham Virtual Healthcare ConferenceVANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference. Absci management is scheduled to participate in a fireside chat on Thursday, April 16th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: investors.absci.com. About Absci Absci is advancing the future of drug discovery with generative design to create better bio
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Absci CorporationSCHEDULE 13D/A - Absci Corp (0001672688) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Absci CorporationSCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
- SECSEC Form S-8 filed by Absci CorporationS-8 - Absci Corp (0001672688) (Filer)
- SECSEC Form 10-K filed by Absci Corporation10-K - Absci Corp (0001672688) (Filer)
- SECAbsci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
ABSI FAQ
7 questionsWhat does Absci Corporation do?
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.Where does ABSI stock trade?
Absci Corporation (ABSI) is listed on NASDAQ.What sector and industry is ABSI in?
Absci Corporation operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Absci Corporation go public?
Absci Corporation (ABSI) completed its IPO in 2021.What are analysts saying about ABSI?
Absci Corporation has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $1200.00 price target on 2026-06-04. Recent price targets range from $432.00 to $1200.00.What companies are similar to ABSI?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare ABSI side-by-side with any of them on Quantisnow.How can I track ABSI on Quantisnow?
Quantisnow aggregates Absci Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABSI to receive live email and push alerts on every new disclosure.